Thor Halfdanarson Explores First-Line Treatment Choices for Advanced Neuroendocrine Tumors
Thor Halfdanarson/mayoclinic.org

Thor Halfdanarson Explores First-Line Treatment Choices for Advanced Neuroendocrine Tumors

Thor Halfdanarson, Professor of Oncology at Mayo Clinic School of Medicine, shared a post on X:

“Time for another NET talk – this time on sequencing of systemic therapy. Another excellent Mayo Clinic Med Ed offering. If you are looking for a good course in pretty much anything in Med Ed, check them out.

They have a huge selection of quality courses, not just in oncology.

So how to we select initial therapy for advanced NETs when resection or other regional therapy is not a good option…?

Below are some thoughts, as always open to criticism and and comments (snarky comments also welcomed if you feel so inclined…).

Come join us for future Mayo Clinic conferences!

Or see yours truly in Minneapolis for a day-long crash course in oncology updates – well, we have that too.”

Thor Halfdanarson

Other articles about NET on OncoDaily.